Skip to main content

Webinar: Making Monoclonal Antibodies Broadly Accessible to Communities Most At Risk Of HIV/AIDS – What Would It Take?

A webinar in partnership with IAVI

The Global HIV Vaccine Enterprise of the IAS – the International AIDS Society – and IAVI organized an online event on 23 November 2020 to discuss challenges and opportunities in access to future monoclonal antibodies for HIV prevention.

Challenges and opportunities on the access to future monoclonal antibodies for HIV prevention

The webinar is introduced by Mark Feinberg, CEO and President of IAVI, interviewed by Chloe Orkin, Clinical Professor of HIV Medicine at Queen Mary University of London, and Chair of the British HIV Association (BHIVA). This is followed by perspectives of a renowned panel of experts on R&D, manufacturing, access, policy and regulation. It concludes with an audience Q&A.

The panel includes:

  • Mike Cohen, Director, Institute for Global Health and Infectious Diseases, UNC School of Medicine, USA
  • Helen Rees, Executive Director of the Wits Reproductive Health and HIV Institute at the University of the Witwatersrand, South Africa
  • Rosemary Mburu, Executive Director WACI Health, Kenya
  • Erin Sparrow, Technical Officer, Vaccine Product and Delivery Research Immunization, Vaccines and Biologicals, World Health Organization, Geneva
  • Bill Snow, HIV activist
  • Co-Chairs: Hester Kuipers (IAVI) and Roger Tatoud (the Enterprise)

The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.